Original news and analysis on international IP policy
The members of the World Health Organization Executive Board tonight (24 January) agreed to create a roadmap on global shortages of, and access to, medicines and vaccines. WHO members proclaimed the urgent need to address prices and availability of safe and efficient medicines and vaccines, some requesting the recently elected director general of the organisation to help find solutions.
World Health Organization Executive Board members and observer countries today are preparing to discuss recommendations on ways to lower prices and make medicines more accessible. This includes a new proposal to increase transparency in research and development costs that is reportedly causing concern among some developed countries.
Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos.
Three new draft proposals at the World Health Organization Executive Board this week underline the importance of access and affordability, whether it is vaccines and medicines, including antivenoms, or assistive technology. The draft resolutions call on member states as well as the WHO secretariat to urgently take action to facilitate access to products and technologies at affordable prices.
Three major international organisations in Geneva dealing with health, trade and intellectual property rights will come together next month to look at how innovative technologies can help to achieve the UN Sustainable Development Goals related to health.
All human beings should receive the health services they need without suffering financial hardship, such is the definition of universal health coverage, a key point of discussion at the World Health Organization Executive Board meeting this week. New WHO Director General Tedros Adhanom Ghebreyesus (Dr Tedros) opened the event by presenting his vision for the future, and the collective work to accomplish necessary changes to the UN health agency. The European Union and United States warned against politicisation of the WHO.
The United States, possibly working with like-minded countries, is working to prevent the further spread among international organisations in Geneva of recommendations put forward by the 2016 United Nations High-Level Panel on Access to Medicines, considering them to be ideological driven and dangerous to economic growth. The comments were made by a US official speaking to a recent US industry event in Washington DC involving many of the US intellectual property attachès, at which two attachés from Geneva described latest developments and strategy for the coming year. A key message from attachès to industry: come to Geneva and engage, starting with this week’s Executive Board meeting at the World Health Organization.
The end of 2017 and start of 2018 brought a lot of changes in the global intellectual property arena. The World Health Organization underwent major changes in its leadership following a new head elected in May, UNAIDS has a new deputy executive director, the World Intellectual Property Organization is seeking a new leader of its Global Challenges division, and the Board of the Internet Corporation for Assigned Names and Numbers decided on a number of appointments. The European Patent Office elected a new president, and the industry world also saw its share of changes. The International Federation of Pharmaceutical Manufacturers and Associations welcomed some new faces, and the head of the Federation of the European Sporting Goods Industry is changing. Law firms saw a high level of revolving chair movements, and promotions of attorneys to partners.
On the eve of the annual January World Health Organization Executive Board meeting, an alliance of pharmaceutical industries launched its first report on efforts made to curb antimicrobial resistance. The alliance also organised a conference on the report and on challenges of antimicrobial resistance, in particular the need for research and development incentives so that the industry can continue its efforts sustainably. Some light was also shed on the need to support access to diagnostics, and lower their prices.
At the dawn of 2018, political and health leaders must seize the growing momentum and opportunities to tackle the protracted challenges of access to medicines that undermines efforts to save lives and improve health as committed under the Agenda 2030 SDG [Sustainable Development Goals] by all UN member states, write Jorge Bermudez and Viroj Tangcharoensathien.